Patent intelligence · US
US 11654145
Combination therapy involving diaryl macrocyclic compounds
Combination therapy involving diaryl macrocyclic compounds
Patent details — US 11654145
- Jurisdiction
- US
- Status
- granted
- Grant date
- May 23, 2023
- Expiration
- May 18, 2043
- Applicant
- TURNING POINT THERAPEUTICS, INC.
- Claims
- 30
- CPC classes
- A61K, A61K31/517, A61K31/519, A61K45/06
Quick answer
US 11654145 (Combination therapy involving diaryl macrocyclic compounds) is held by TURNING POINT THERAPEUTICS, INC.. Status: granted. Granted May 23, 2023. Expires May 18, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- TURNING POINT THERAPEUTICS, INC.
- Grant date
- Expiration
- Claims
- 30
- CPC classes
- A61K, A61K31/517, A61K31/519, A61K45/06, A61P, A61P35/00
More from TURNING POINT THERAPEUTICS, INC.
Related pharmaceutical patents in our USPTO index.
-
US 12310968
Chiral diaryl macrocycles and uses thereof
granted -
US 12252488
HPK1 antagonists and uses thereof
granted -
US 12215105
HPK1 antagonists and uses thereof
granted -
US 12187739
Diaryl macrocycle polymorph
granted -
US 12071442
Substituted pyrrolo[3,4-c]pyridines as HPK1 antagonists
granted -
US 11981684
Macrocyclic compounds and uses thereof
granted -
US 11926625
HPK1 antagonists and uses thereof
granted -
US 11802292
Modified orthopoxvirus vectors
granted
Frequently asked questions
What is US patent 11654145?
US 11654145 (Combination therapy involving diaryl macrocyclic compounds) is held by TURNING POINT THERAPEUTICS, INC.. Status: granted. Granted May 23, 2023. Expires May 18, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11654145?
TURNING POINT THERAPEUTICS, INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 40 pharmaceutical patents for this assignee.
When does US 11654145 expire?
Our index shows an expiration date of May 18, 2043 (17 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.